Solvemed Group
Mateusz Wodzik is an experienced finance professional currently serving as Finance Manager at Solvemed Group since October 2022, responsible for all finance-related processes across the USA, UK, and Poland. Previously, Mateusz held the role of Acting CFO at RealCo Property Investment and Development, implementing budgeting and cost control processes. As a Senior Investment Analyst at Warsaw Equity Group, responsibilities included investment project evaluation and portfolio supervision. Prior roles include Senior Financial Analyst at CC Group sp zoo, where Mateusz focused on financial modeling and investment documentation, and Fund Analyst at Citi, managing fund portfolio valuations. Mateusz began a career in finance as an Analyst/Intern at Crédit Agricole CIB. Educational qualifications include a Master of Science in Finance and Accounting from SGH Warsaw School of Economics and a Bachelor of Applied Science in Finance and Accounting from Poznan University of Economics and Business.
This person is not in any teams
This person is not in any offices
Solvemed Group
At Solvemed Group, we believe in challenging the status quo of neurological care. Our founders experienced first-hand the grave consequences of poor diagnostic standards in neurodegenerative diseases. With the primary focus in Parkinson’s disease, we leverage our proprietary machine learning technology to develop novel diagnostic-predictive digitalbiomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools. In everything we do, we put the needs of patients and healthcare professionals first. We also happen to revolutionise drug discovery as our biomarkers enable disease-modifying drugs.We respond to the unmet needs of neurological patients by providing reliable, accurate, early diagnostics and monitoring tools for better quality care and treatment outcomes. Our work has the potential to improve healthcare systems by optimising relevant care pathways and reducing the financial burden imposed by inadequate diagnostics. Through our proprietary medical data repositories, we work with our biopharmaceutical industry partners driving clinical trial efficiency and making first-in-class disease-modifying drugs possible.Everything we do is strongly embedded in world-class science. Our global team of renowned scientists and technology experts works closely with clinical researchers from top research institutions, such as Oxford University, University College London, Harvard Medical School and Duke University, among other.